Esophageal Cancer Drugs Market Size Acquire US$ 1,547.8 Million Grabbing a CAGR of 8.2% by 2027 | Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche,

The global esophageal cancer drugs market size was valued at US$ 765.2 million in 2018 and is expected to witness a CAGR of 8.2% over the forecast period (2019 – 2027).

Global Esophageal Cancer Drugs Market: Drivers 

R&D in cancer treatment is expected to propel growth of the global esophageal cancer drugs market over the forecast period. For instance, in December 2018, National Cancer Center Hospital, Tokyo, started a clinical trial that assessed the comparative study between combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus. Similarly, in February 2019, a study from Case Western Reserve University, U.S. reported that JNK/TGF-beta-targeted therapy can be effective in treatment of esophageal cancer as blocking two molecular pathways that send signals inside cancer cells can help in treatment of esophageal adenocarcinoma.

Moreover, high prevalence of cancer is also expected to propel growth of the global esophageal cancer drugs market over the forecast period. For instance, the according to American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 @ https://www.coherentmarketinsights.com/insight/request-pdf/3036

Market Trends

Age, gender, tobacco, alcohol, Barrett’s esophagus, obesity, and achalasia influence esophageal cancer. Achalasia patients have 50 times higher risk of incidence of esophageal squamous cell carcinoma than the general population, according to a study published in National Center for Biotechnology Information in 2017 and the overall prevalence of achalasia is 9 to 10 in 100,000 people annually, worldwide.

As per the World Cancer Research Fund International report of 2018, highest rate of esophageal cancer was found in Malawi, Mongolia, Kenya, and Bangladesh. Thus, high prevalence of the condition in emerging economies is expected to propel growth of the global esophageal cancer drugs market.

Global Esophageal Cancer Drugs Market: Restraints  

High cost of treatment and side effects of drugs are some of the factors hindering growth of the global esophageal cancer drugs market. Drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel that are used in treatment of esophageal cancer can lead to damage to nerves outside the brain and spinal cord. Moreover, in 2013, cancer patients paid US$ 207,000 annually for the treatment and medications, compared to US$ 54,100 annually, in 1995, according to a report published in Healthday.

Global Esophageal Cancer Drugs Market: Competitive Landscape

Major players operating in the global esophageal cancer drugs market include, Amgen Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline Plc., Gilead Sciences, Genentech, Inc., Johnson & Johnson, Merck & Co., Novartis AG, and Sanofi-Aventis.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/promo/buynow/3036

Global Esophageal Cancer Drugs Market: Segmentation 

On the basis of therapy type, the global esophageal cancer drugs market is segmented into:

• Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
• Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
• Immunotherapy
  • Pembrolizumab

On the basis of disease indication, the global esophageal cancer drugs market is segmented into:

• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others

On the basis of distribution channel, the global esophageal cancer drugs market is segmented into:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

On the basis of region, the global esophageal cancer drugs market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Overview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Therapy Type
     • Market Snippet, By Disease Indication
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Market Trends
   • Key Developments
   • Regulatory Landscape
   • Product Recall
   • Epidemiology Analysis
   • Technology Overview
   • PEST Analysis
   • Porter’s Five Forces model
4. Global Esophageal Cancer Drugs Market, By Therapy Type,  2019 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Chemotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
       • Docetaxel
       • Irinotecan
       • Trifluridine and tipiracil
       • Carboplatin and paclitaxel
       • Cisplatin and 5-fluorouracil
       • Cisplatin with capecitabine
   • Targeted Drug Therapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
       • Trastuzumab
       • Ramucirumab
   • Immunotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
       • Pembrolizumab
5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2019 – 2027, (US$ Million)
   •  Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Adenocarcinomas
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Gastrointestinal Stromal Tumors
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Carcinoid Tumors
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Squamous Cell Carcinoma
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
6. Global Esophageal Cancer Drugs Market, By Distribution Channel 2019 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospital Pharmacy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Retail Pharmacy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
   • Online Pharmacy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)

View Press Release: https://www.coherentmarketinsights.com/press-release/esophageal-cancer-drugs-market-to-surpass-us-15478-million-by-2027-2491